Influence of delayed initiation of therapy on the course of disease in hepatocellular carcinoma

Influence of delayed initiation of therapy on the course of disease in hepatocellular carcinoma - Staging in HCC - LMU-RAD01174

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033834

Enrollment

900

Registered

2024-05-24

Start date

2024-05-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22

Interventions

Group 1: The hospital's electronic database will be searched for all patients who received a diagnosis of HCC. Clinical and laboratory data are collected for each patient from the electronic medical r

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - HCC patients =18 years - Presence of multiphasic cross-sectional imaging (MRI and CT) at initial diagnosis and immediately prior to local therapy - No additional treatment of HCC prior to local therapy

Exclusion criteria

Exclusion criteria: - Incomplete or insufficient imaging that impairs correct image interpretation (e.g. due to artifacts or lack of the correct contrast agent phases).

Design outcomes

Primary

Measure	Time frame
The study aims to gain valuable insights from existing data to deepen the understanding of the impact of delayed treatment initiation on disease progression in hepatocellular carcinoma.	—

Secondary

Measure	Time frame
Definition of the optimal time interval between HCC diagnosis and initiation of local therapy.	—

Countries

Germany

Contacts

Public ContactMax Seidensticker

LMU

max.seidensticker@med.uni-muenchen.de+49 89 4400-76642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026